Advertisement
Johnson & Johnson
Subscribe to Johnson & Johnson

The Lead

Carna announces collaboration with J&J

June 11, 2015 11:22 am | by Business Wire | News | Comments

Carna Biosciences today announced a worldwide licensing agreement with Janssen Biotech to further develop and commercialize compounds from one of Carna Bioscience’s small molecule protein kinase inhibitor programs.

Johnson & Johnson starts project to prevent Type 1 diabetes

June 11, 2015 11:04 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

It's the healthcare giant's first project under its ambitious initiative to prevent or at least...

J&J opens new schizophrenia project

June 9, 2015 11:20 am | by PR Newswire | News | Comments

The project will create a new forum for collaborative analysis of Janssen's clinical trial data...

J&J pipeline forecasting 10 new products worth $1B

June 2, 2015 12:14 pm | by PR Newswire | News | Comments

Senior leaders announced plans to file for regulatory approval of more than 10 new products...

View Sample

FREE Email Newsletter

J&J Pharmaceuticals Announces 10 filings for Blockbuster Drugs by 2019

May 20, 2015 10:43 am | News | Comments

At a meeting today with analysts, Johnson & Johnson's Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to ...

J&J Settles $7.8 Million Lawsuit

May 19, 2015 10:35 am | by AP | News | Comments

Three years ago a jury found that a subsidiary, Janssen Pharmaceutical, committed Medicaid fraud and violated a state law in its labeling and marketing of Risperdal. A $1.2 billion fine was initially imposed on Johnson & Johnson.

J&J Seeks Bioethics Advice on Compassionate Use of Drugs

May 7, 2015 11:39 am | by Lauran Neergaard, AP Medical Writer | News | Comments

Now drug giant Johnson & Johnson is taking an unusual step, turning to independent bioethicists for advice.

Advertisement

McNeil Consumer Healthcare Pleads Guilty to Metal Particles in Kids' Tylenol

March 11, 2015 8:23 am | by MICHAEL RUBINKAM, Associated Press; MARYCLAIRE DALE, Associated Press | News | Comments

McNeil Consumer Healthcare, of Fort Washington, Pennsylvania, acknowledged failing to take corrective action after discovering the adulterated bottles of Infants' and Children's Tylenol and Children's Motrin. The company agreed to pay $25 million to resolve the case.

Johnson & Johnson Innovation Announces New Startup Campus

March 3, 2015 2:17 pm | by Andy Szal, Digital Reporter | News | Comments

The venture capital arm of the New Jersey consumer products giant officially unveiled its JLABS@South San Francisco campus Monday. The 30,000-square foot incubator will eventually house up to 50 startups.

Cardinal Health to Acquire J&J’s Cordis for $1.944B

March 2, 2015 8:32 am | News | Comments

Cardinal Health today announced plans to acquire Johnson & Johnson's Cordis business, a global manufacturer of cardiology and endovascular devices, for $1.944 billion in cash, or approximately $1.594 billion, net of the present value of tax benefits.

Court: J&J Must Pay South Carolina $136M for Deceptive Drug Marketing

February 27, 2015 8:00 am | by MEG KINNARD, Associated Press | News | Comments

South Carolina's high court says a Johnson & Johnson subsidiary should pay the state $136 million over deceptive drug marketing of an anti-psychotic drug.

Boston Scientific to Pay Johnson & Johnson $600M

February 18, 2015 8:13 am | News | Comments

Boston Scientific will pay $600 million to settle with drugmaker Johnson & Johnson over the medical device maker's $27 billion acquisition of Guidant Corp. in 2006.

Advertisement

Johnson & Johnson Projects Aim to Spot Who Will Get a Disease

February 12, 2015 8:05 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

This isn't a science fiction tale. It's the ambitious goal of three research projects just launched by Johnson & Johnson's pharmaceutical research arm, Janssen Research & Development, that the company says are aimed at redefining health care.

Johnson & Johnson Tops Fourth Quarter Earnings Expectations

January 21, 2015 8:05 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

The strong dollar and stiff competition for some products squeezed J&J in the fourth quarter and it missed Wall Street expectations for revenue, triggering a rare sell-off of its shares. The world's biggest maker of health care products did edge past profit forecasts and there were other bright spots, including a 10% jump in prescription drug sales and increasing use of medical care in the U.S.

Johnson & Johnson Ebola Groups Get $117M in Funding

January 19, 2015 9:37 am | News | Comments

Johnson & Johnson is working with a slew of organizations to speed up development of an Ebola vaccine, and the company said Friday that a European health organization awarded them $117 million.         

Evotec Achieves Milestones in TargetAD Collaboration With Janssen

January 15, 2015 2:31 pm | News | Comments

Evotec AG has announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.

Pharmacyclics Reports Good Revenue from Imbruvica

January 13, 2015 9:38 am | by The Associated Press | News | Comments

Shares of Pharmacyclics jumped Tuesday morning after the cancer treatment developer announced better-than-expected revenue forecasts for Imbruvica, a leukemia drug it sells with a Johnson & Johnson subsidiary.      

Advertisement

Johnson & Johnson Licenses Vedanta's Bowel Disease Drug

January 13, 2015 8:31 am | News | Comments

Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.         

Johnson & Johnson Begins Ebola Vaccine Testing in Humans

January 6, 2015 7:57 am | News | Comments

J&J said that the first volunteers have received an initial dose and that, in a partnership with Bavarian Nordic AS, more than 400,000 regimens of the prime-boost vaccine have been produced for use in large-scale clinical trials by April 2015.  

J&J Named Happiest Company to Work For

December 11, 2014 8:15 am | News | Comments

CareerBliss has announced the 5th annual CareerBliss 50 Happiest Companies in America awards list. The list honors the top companies dedicated to creating happier work environments - as voted for by their own employees.     

Drugmakers Bet on Ebola Vaccines, Treatments

October 26, 2014 9:33 am | by Matthew Perrone - Associated Press - Associated Press | News | Comments

Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.    

J&J to Spend Up to $200M on Ebola Vaccine Program

October 22, 2014 8:09 am | News | Comments

Johnson & Johnson will start safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus. The company has committed up to $200M to speed up and expand production of a vaccine program being developed by its Janssen Pharmaceutical Companies.

Aduro Expands Collaboration with Johnson & Johnson Innovation and Janssen for Lung Cancer Immunotherapies

October 17, 2014 8:40 am | News | Comments

Under the agreement, facilitated by the Johnson & Johnson Innovation center in California, Aduro will receive a $30M up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817M.

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin Lymphoma

October 14, 2014 8:48 am | News | Comments

The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

J&J Beats Wall Street Third Quarter Forecasts

October 14, 2014 8:06 am | News | Comments

Johnson & Johnson has reported third-quarter earnings of $4.75 billion. The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.    

Johnson & Johnson Buying Alios for $1.75B

September 30, 2014 9:48 am | by The Associated Press | News | Comments

Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The deal includes Alios' portfolio of potential therapeutics for viral infections.

Johnson & Johnson to Accelerate Ebola Vaccine Program

September 4, 2014 8:43 am | News | Comments

Johnson & Johnson will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate with its partners in global health to deliver immediate relief aid to address the current Ebola outbreak.

J&J Withdraws Fibroid Treatment Device from Market

July 30, 2014 7:33 pm | by The Associated Press | News | Comments

Johnson & Johnson is asking surgeons not to use a line of devices for removing growths from the uterus amid regulators' growing concern that the electronic surgical tools raise the risk of spreading cancer to other parts of the body.  

J&J Buying Back $5B Worth of its Shares

July 21, 2014 6:26 pm | by The Associated Press | News | Comments

Johnson & Johnson, the world's biggest maker of health care products, plans to buy back up to $5 billion of the company's common stock. The maker of prescription drugs, medical devices and Tylenol said Monday that its board of directors had approved the stock buyback program.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading